CD274 and melanoma: Research has demonstrated that the interaction between programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) is a critical immune checkpoint, and inhibiting PD-1 has been found to exhibit high treatment efficacy for melanoma and is now approved for the treatment of HNSC [8, 9].